Navigation Links
Sinovac Files Shelf Registration Statement
Date:11/18/2009

BEIJING, Nov. 18 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA), a leading developer and provider of vaccines, announced today that it has filed a shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, remarked, "The shelf registration is intended to provide us with greater financial flexibility to execute our growth strategy over the next several years. It is important to note that we do not have immediate plans to raise capital."

If and when the shelf registration statement on Form F-3 is declared effective by the SEC, Sinovac may from time to time offer and sell up to 10 million common shares. The use of the net proceeds from the sale of the common shares will be set forth in the applicable prospectus supplement filed each time common shares are sold.

The registration statement has been filed with the SEC, but has not yet become effective. The terms of any offering under the registration statement would be established at the time of the offering and as required would be described in a prospectus supplement filed with the SEC. The common shares may not be sold, nor may offers to buy the common shares be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell any common shares, or the solicitation of an offer to buy any common shares, nor will Sinovac sell any common shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the laws of any such state or jurisdiction.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (seasonal influenza), Panflu(TM) (pandemic influenza (H5N1)), and PANFLU.1(TM) (pandemic influenza A (H1N1)).

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    For more information, please contact:

    Helen G. Yang
    Sinovac Biotech Ltd.
    Tel:   +86-10-8289-0088 x9871
    Fax:   +86-10-6296-6910
    Email: info@sinovac.com

    Investors:
     Amy Glynn/Stephanie Carrington
     The Ruth Group
     Tel:   +1-646-536-7023/7017
     Email: aglynn@theruthgroup.com
            scarrington@theruthgroup.com

    Media:
     Janine McCargo
     The Ruth Group
     Tel:   +1-656-536-7033
     Email: jmccargo@theruthgroup.com

SOURCE Sinovac Biotech Ltd.


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovacs PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population
2. Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive(R)
3. Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine
4. Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
5. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
6. deCODE genetics, Inc. Files Voluntary Chapter 11 Petition to Facilitate Sale of Assets
7. Derma Sciences Files S-1 Registration Statement
8. Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering
9. Labopharm files New Drug Submission with Health Canada for novel antidepressant
10. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
11. Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... , Feb. 17, 2017   Parker ... protecting the rights of victims injured by medical ... regulators to call for better reporting. Congress required ... Safety concerns involving power morcellators and duodenoscopes ... to investigate how hospitals report injuries and deaths ...
(Date:2/17/2017)... February 17, 2017 Cryoablation, Electrical, Endometrial Hydrothermal, ... The global ablation technologies market is expected to grow at a ... The market is expected to grow at a CAGR of 9.5% ... 2016, and $9.05bn in 2026. ... How this report will benefit you Read on ...
(Date:2/17/2017)... 2017 Arvinas LLC, a private biotechnology company ... degradation, today announced the presentation of new preclinical data ... poster session at the American Society of Clinical Oncology ... Orlando, FL. "The new ... the potential of PROTACs to drive durable and robust ...
Breaking Medicine Technology:
(Date:2/17/2017)... Tampa, FL (PRWEB) , ... February 17, 2017 ... ... a premier sponsor and exhibitor at Molecular Medicine Tri-Conference February 20 – 22 ... through Wednesday, Inspirata will showcase its anatomic and molecular pathology workflow solution, as ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists ... from February 21 - 23 in Beaver Creek, CO. It was announced today by ... second year in Beaver Creek, hosting over 60 faculty members and addressing unmet needs ...
(Date:2/17/2017)... FL (PRWEB) , ... February 17, 2017 , ... ... services and financial planning assistance to families and business owners in the greater ... LifeNet 4 Families organization. , For more than 30 years, LifeNet 4 ...
(Date:2/16/2017)... ... 17, 2017 , ... For some cancer survivors, the memories ... Physician researchers at The Marcus Institute of Integrative Health at Thomas Jefferson ... reducing symptoms of traumatic stress in cancer patients and published their results ...
(Date:2/16/2017)... ... 2017 , ... The Price Agency, a Jefferson County-based firm ... the Birmingham area, is announcing an ongoing charity event to help raise support ... son, Anius. , Anius is medically complex with diagnoses consisting and not limited ...
Breaking Medicine News(10 mins):